Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
NCT04103645 · Weill Medical College of Cornell University · PHASE2 · terminated · last registry update 2025-07-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | – | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TGFBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-07Phase 3 first posted: Gipfel Life Sciences GmbH, Galunisertib + Nerandomilast Combination (NCT07321860)
- 2025-12-31Results posted on the registry: Chloe Atreya, MD, PhD, Pembrolizumab + Vactosertib (NCT03844750)
- 2025-12-31Also stopped (terminated): Chloe Atreya, MD, PhD, Pembrolizumab + Vactosertib (NCT03844750)
- 2025-11-24Results posted on the registry: Eli Lilly and Company, Galunisertib + Lomustine (NCT01582269)
- 2025-04-02Also stopped (terminated): Yonsei University, Pembrolizumab, Vactosertib (NCT05436990)
- 2024-12-09Also stopped (withdrawn): MedPacto, Inc., Vactosertib(TEW-7197)/ Durvalumab (NCT04064190)
- 2024-12-09Also stopped (withdrawn): MedPacto, Inc., Vactosertib + Imatinib (NCT06219733)
- 2024-12-09Also stopped (terminated): MedPacto, Inc., Vactosertib 300 mg BID and pembrolizumab 200 mg IV (NCT04515979)
- 2024-08-07Results posted on the registry: University of Oklahoma, Galunisertib + Paclitaxel (NCT03206177)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision